Circulating miRNA panels for specific and early detection in bladder cancer

Wataru Usuba, Fumihiko Urabe, Yusuke Yamamoto, Juntaro Matsuzaki, Hideo Sasaki, Makiko Ichikawa, Satoko Takizawa, Yoshiaki Aoki, Shumpei Niida, Ken Kato, Shin Egawa, Tatsuya Chikaraishi, Hiroyuki Fujimoto, Takahiro Ochiya

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Bladder cancer is the 9th leading cause of cancer death worldwide. The major problem in bladder cancer is primarily the high recurrence rate after drug treatment and resection. Although conventional screening methods, such as cystoscopy, urinary cytology and ultrasound sonography, have become widely used in clinical settings, the diagnostic performance of these modalities is unsatisfactory due to low accuracy or high invasiveness. Because circulating micro RNA (miRNA) profiles have recently been reported as an attractive tool for liquid biopsy in cancer screening, here, we performed global miRNA profiling of 392 serum samples of bladder cancer patients with 100 non-cancer samples and 480 samples of other types of cancer as controls. We randomly classified the bladder cancer and control samples into 2 cohorts, a training set (N = 486) and a validation set (N = 486). By comparing both controls, we identified specific miRNA, such as miR-6087, for diagnosing bladder cancer in the training and validation sets. Furthermore, we found that a combination of 7 miRNA (7-miRNA panel: miR-6087, miR-6724-5p, miR-3960, miR-1343-5p, miR-1185-1-3p, miR-6831-5p and miR-4695-5p) could discriminate bladder cancer from non-cancer and other types of tumors with the highest accuracy (AUC:.97; sensitivity: 95%; specificity: 87%). The diagnostic accuracy was high, regardless of the stage and grade of bladder cancer. Our data demonstrated that the 7-miRNA panel could be a biomarker for the specific and early detection of bladder cancer.

Original languageEnglish
Pages (from-to)408-419
Number of pages12
JournalCancer Science
Volume110
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1
Externally publishedYes

Fingerprint

MicroRNAs
Urinary Bladder Neoplasms
Early Detection of Cancer
Neoplasms
Cystoscopy
Area Under Curve
Cell Biology
Cause of Death
Ultrasonography
Biomarkers
Biopsy
Recurrence
Serum
Pharmaceutical Preparations

Keywords

  • bladder cancer
  • circulating microRNA
  • diagnosis
  • early detection
  • liquid biopsy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Usuba, W., Urabe, F., Yamamoto, Y., Matsuzaki, J., Sasaki, H., Ichikawa, M., ... Ochiya, T. (2019). Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Science, 110(1), 408-419. https://doi.org/10.1111/cas.13856

Circulating miRNA panels for specific and early detection in bladder cancer. / Usuba, Wataru; Urabe, Fumihiko; Yamamoto, Yusuke; Matsuzaki, Juntaro; Sasaki, Hideo; Ichikawa, Makiko; Takizawa, Satoko; Aoki, Yoshiaki; Niida, Shumpei; Kato, Ken; Egawa, Shin; Chikaraishi, Tatsuya; Fujimoto, Hiroyuki; Ochiya, Takahiro.

In: Cancer Science, Vol. 110, No. 1, 01.01.2019, p. 408-419.

Research output: Contribution to journalArticle

Usuba, W, Urabe, F, Yamamoto, Y, Matsuzaki, J, Sasaki, H, Ichikawa, M, Takizawa, S, Aoki, Y, Niida, S, Kato, K, Egawa, S, Chikaraishi, T, Fujimoto, H & Ochiya, T 2019, 'Circulating miRNA panels for specific and early detection in bladder cancer', Cancer Science, vol. 110, no. 1, pp. 408-419. https://doi.org/10.1111/cas.13856
Usuba, Wataru ; Urabe, Fumihiko ; Yamamoto, Yusuke ; Matsuzaki, Juntaro ; Sasaki, Hideo ; Ichikawa, Makiko ; Takizawa, Satoko ; Aoki, Yoshiaki ; Niida, Shumpei ; Kato, Ken ; Egawa, Shin ; Chikaraishi, Tatsuya ; Fujimoto, Hiroyuki ; Ochiya, Takahiro. / Circulating miRNA panels for specific and early detection in bladder cancer. In: Cancer Science. 2019 ; Vol. 110, No. 1. pp. 408-419.
@article{bed3bc6e11d64c60b8799fa1881a3987,
title = "Circulating miRNA panels for specific and early detection in bladder cancer",
abstract = "Bladder cancer is the 9th leading cause of cancer death worldwide. The major problem in bladder cancer is primarily the high recurrence rate after drug treatment and resection. Although conventional screening methods, such as cystoscopy, urinary cytology and ultrasound sonography, have become widely used in clinical settings, the diagnostic performance of these modalities is unsatisfactory due to low accuracy or high invasiveness. Because circulating micro RNA (miRNA) profiles have recently been reported as an attractive tool for liquid biopsy in cancer screening, here, we performed global miRNA profiling of 392 serum samples of bladder cancer patients with 100 non-cancer samples and 480 samples of other types of cancer as controls. We randomly classified the bladder cancer and control samples into 2 cohorts, a training set (N = 486) and a validation set (N = 486). By comparing both controls, we identified specific miRNA, such as miR-6087, for diagnosing bladder cancer in the training and validation sets. Furthermore, we found that a combination of 7 miRNA (7-miRNA panel: miR-6087, miR-6724-5p, miR-3960, miR-1343-5p, miR-1185-1-3p, miR-6831-5p and miR-4695-5p) could discriminate bladder cancer from non-cancer and other types of tumors with the highest accuracy (AUC:.97; sensitivity: 95{\%}; specificity: 87{\%}). The diagnostic accuracy was high, regardless of the stage and grade of bladder cancer. Our data demonstrated that the 7-miRNA panel could be a biomarker for the specific and early detection of bladder cancer.",
keywords = "bladder cancer, circulating microRNA, diagnosis, early detection, liquid biopsy",
author = "Wataru Usuba and Fumihiko Urabe and Yusuke Yamamoto and Juntaro Matsuzaki and Hideo Sasaki and Makiko Ichikawa and Satoko Takizawa and Yoshiaki Aoki and Shumpei Niida and Ken Kato and Shin Egawa and Tatsuya Chikaraishi and Hiroyuki Fujimoto and Takahiro Ochiya",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/cas.13856",
language = "English",
volume = "110",
pages = "408--419",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Circulating miRNA panels for specific and early detection in bladder cancer

AU - Usuba, Wataru

AU - Urabe, Fumihiko

AU - Yamamoto, Yusuke

AU - Matsuzaki, Juntaro

AU - Sasaki, Hideo

AU - Ichikawa, Makiko

AU - Takizawa, Satoko

AU - Aoki, Yoshiaki

AU - Niida, Shumpei

AU - Kato, Ken

AU - Egawa, Shin

AU - Chikaraishi, Tatsuya

AU - Fujimoto, Hiroyuki

AU - Ochiya, Takahiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Bladder cancer is the 9th leading cause of cancer death worldwide. The major problem in bladder cancer is primarily the high recurrence rate after drug treatment and resection. Although conventional screening methods, such as cystoscopy, urinary cytology and ultrasound sonography, have become widely used in clinical settings, the diagnostic performance of these modalities is unsatisfactory due to low accuracy or high invasiveness. Because circulating micro RNA (miRNA) profiles have recently been reported as an attractive tool for liquid biopsy in cancer screening, here, we performed global miRNA profiling of 392 serum samples of bladder cancer patients with 100 non-cancer samples and 480 samples of other types of cancer as controls. We randomly classified the bladder cancer and control samples into 2 cohorts, a training set (N = 486) and a validation set (N = 486). By comparing both controls, we identified specific miRNA, such as miR-6087, for diagnosing bladder cancer in the training and validation sets. Furthermore, we found that a combination of 7 miRNA (7-miRNA panel: miR-6087, miR-6724-5p, miR-3960, miR-1343-5p, miR-1185-1-3p, miR-6831-5p and miR-4695-5p) could discriminate bladder cancer from non-cancer and other types of tumors with the highest accuracy (AUC:.97; sensitivity: 95%; specificity: 87%). The diagnostic accuracy was high, regardless of the stage and grade of bladder cancer. Our data demonstrated that the 7-miRNA panel could be a biomarker for the specific and early detection of bladder cancer.

AB - Bladder cancer is the 9th leading cause of cancer death worldwide. The major problem in bladder cancer is primarily the high recurrence rate after drug treatment and resection. Although conventional screening methods, such as cystoscopy, urinary cytology and ultrasound sonography, have become widely used in clinical settings, the diagnostic performance of these modalities is unsatisfactory due to low accuracy or high invasiveness. Because circulating micro RNA (miRNA) profiles have recently been reported as an attractive tool for liquid biopsy in cancer screening, here, we performed global miRNA profiling of 392 serum samples of bladder cancer patients with 100 non-cancer samples and 480 samples of other types of cancer as controls. We randomly classified the bladder cancer and control samples into 2 cohorts, a training set (N = 486) and a validation set (N = 486). By comparing both controls, we identified specific miRNA, such as miR-6087, for diagnosing bladder cancer in the training and validation sets. Furthermore, we found that a combination of 7 miRNA (7-miRNA panel: miR-6087, miR-6724-5p, miR-3960, miR-1343-5p, miR-1185-1-3p, miR-6831-5p and miR-4695-5p) could discriminate bladder cancer from non-cancer and other types of tumors with the highest accuracy (AUC:.97; sensitivity: 95%; specificity: 87%). The diagnostic accuracy was high, regardless of the stage and grade of bladder cancer. Our data demonstrated that the 7-miRNA panel could be a biomarker for the specific and early detection of bladder cancer.

KW - bladder cancer

KW - circulating microRNA

KW - diagnosis

KW - early detection

KW - liquid biopsy

UR - http://www.scopus.com/inward/record.url?scp=85059465771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059465771&partnerID=8YFLogxK

U2 - 10.1111/cas.13856

DO - 10.1111/cas.13856

M3 - Article

VL - 110

SP - 408

EP - 419

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 1

ER -